Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Classic hypotheses of Alzheimer’s disease (AD) include cholinergic neuron death, acetylcholine (ACh) deficiency, metal ion dynamic equilibrium disorder, and deposition of amyloid and tau. Increased evidence suggests neuroinflammation and oxidative stress may cause AD. However, none of these factors induces AD independently, but they are all associated with the formation of Aβ and tau proteins. Current clinical treatments based on ACh deficiency can only temporarily relieve symptoms, accompanied with many side-effects. Hence, searching for natural neuroprotective agents, which can significantly improve the major symptoms and reverse disease progress, have received great attention. Currently, several bioactive marine products have shown neuroprotective activities, immunomodulatory and anti-inflammatory effects with low toxicity and mild side effects in laboratory studies. Recently, chitosan (CTS), chitooligosaccharide (COS) and their derivatives from exoskeletons of crustaceans and cell walls of fungi have shown neuroprotective and antioxidative effects, matrix metalloproteinase inhibition, anti-HIV and anti-inflammatory properties. With regards to the hypotheses of AD, the neuroprotective effect of CTS, COS, and their derivatives on AD-like changes in several models have been reported. CTS and COS exert beneficial effects on cognitive impairments via inhibiting oxidative stress and neuroinflammation. They are also a new type of non-toxic β-secretase and AChE inhibitor. As neuroprotective agents, they could reduce the cell membrane damage caused by copper ions and decrease the content of reactive oxygen species. This review will focus on their anti-neuroinflammation, antioxidants and their inhibition of β-amyloid, acetylcholinesterase and copper ions adsorption. Finally, the limitations and future work will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Irradiation induces neural precursor-cell dysfunction
Monje, M. L., Mizumatsu, S., Fike, J. R., & Palmer, T. D. (2002) · Nature Medicine · doi:10.1038/nm749 · Cited by 1,271
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 1×
“As natural mucoadhesives with good biocompatibility, CTS and COS are commonly used in mucosal administration of drug [97].”
BackgroundKim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
ALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models
Price, D. L., Tanzi, R. E., Borchelt, D. R., & Sisodia, S. S. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.461 · Cited by 406
Neuronal damage in brain inflammation
Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R., & Zipp, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.2.185 · Cited by 249
Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy
Rassu, G., Soddu, E., Posadino, A. M., Pintus, G., Sarmento, B., Giunchedi, P., & Gavini, E. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.01.031 · Cited by 239 · cited 1×
“By another way, the delivery system of CTS-coated and uncoated solid lipid nanoparticles to obtain an efficient and optimal nose-to-brain transport of BACE1 sinRNA was designed, potentially useful in the treatment of AD [84].”
MethodDá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89 · cited 1×
“(3) Neurofibrillary tangles (NFTs) of tau proteins: tau proteins are microtubule-associated proteins that can maintain the normal axonal transport, microtubule structure stability, phosphorylation, and dephosphorylation in a dynamic equilibrium [22,23].”
Background
Cited by
Avcu, E., Baştan, F. E., Abdullah, H. Z., Rehman, M. A. U., Avcu, Y. Y., & Boccaccini, A. R. (2019) · Progress in Materials Science · doi:10.1016/j.pmatsci.2019.01.001 · Cited by 358
Chitosan and chitosan coating nanoparticles for the treatment of brain disease
Yu, S., Xu, X., Feng, J., Liu, M., & Hu, K. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.012 · Cited by 340
Sources, production and commercial applications of fungal chitosan: A review
Huq, T., Khan, A., Brown, D., Dhayagude, N., He, Z., & Ni, Y. (2022) · Journal of Bioresources and Bioproducts · doi:10.1016/j.jobab.2022.01.002 · Cited by 297
Georgieva, D., Nikolova, D., Vassileva, E., & Kostova, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030829 · Cited by 60
Reviewing the biological activity of chitosan in the mucosa: Focus on intestinal immunity
Moine, L., Canali, M. M., Porporatto, C., & Correa, S. G. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.08.098 · Cited by 28
Metadata
- Authors
- Ouyang, Q.-Q., Zhao, S., Li, S.-D., & Song, C.
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2017-11-07
- Volume
- 15
- Issue
- 11
- Pages
- 322
- ISSN
- 1660-3397 (ISSN-L)
- OpenAlex
- W2767211625
- Cited by
- 79
- References
- 14
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/md15110322
- The paper
- Ouyang, Q.-Q., Zhao, S., Li, S.-D., & Song, C. (2017). Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer’s Disease. Marine Drugs. https://doi.org/10.3390/md15110322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.